These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23097187)

  • 1. Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.
    Kagiyama Y; Kitaura J; Togami K; Uchida T; Inoue D; Matsukawa T; Izawa K; Kawabata KC; Komeno Y; Oki T; Nakahara F; Sato K; Aburatani H; Kitamura T
    Int J Hematol; 2012 Nov; 96(5):638-48. PubMed ID: 23097187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
    Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
    Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
    Yan M; Ahn EY; Hiebert SW; Zhang DE
    Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
    Schessl C; Rawat VP; Cusan M; Deshpande A; Kohl TM; Rosten PM; Spiekermann K; Humphries RK; Schnittger S; Kern W; Hiddemann W; Quintanilla-Martinez L; Bohlander SK; Feuring-Buske M; Buske C
    J Clin Invest; 2005 Aug; 115(8):2159-68. PubMed ID: 16025155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
    Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
    Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
    Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
    Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
    Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
    Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
    Xu M; Li D; Lu Y; Chen GQ
    Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
    Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
    Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
    Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
    Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
    Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
    Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
    Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes.
    Mitkevich VA; Petrushanko IY; Spirin PV; Fedorova TV; Kretova OV; Tchurikov NA; Prassolov VS; Ilinskaya ON; Makarov AA
    Cell Cycle; 2011 Dec; 10(23):4090-7. PubMed ID: 22101339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
    Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
    Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
    DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
    Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
    Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
    Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.